Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Sclerosing diseases of the skin

Kalantari Y., Meier K., Ghoreschi K., Kinberger M., Solimani F.

Narrative Review on Systemic / IV, published in J Dtsch Dermatol Ges (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Dtsch Dermatol Ges (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41030177
PMCID
PMC12548314
DOI
10.1111/ddg.15835
Citations
1

Abstract (original English)

Sclerosing skin diseases comprise a group of distinct dermatological conditions characterized by fibrotic changes that may severely impair patients' quality of life. These conditions often present with cutaneous manifestations and, in some cases, may extend to extracutaneous tissues, potentially resulting in significant morbidity and mortality. This review explores the current understanding of the four most prevalent sclerosing skin diseases - localized scleroderma (morphea), systemic sclerosis (SSc), scleromyxedema, and scleredema adultorum of Buschke - as well as sclerotic conditions induced by external agents. Here, we discuss the pathophysiology, clinical characteristics, and disease course of these entities. In addition, diagnostic tools and treatment options are addressed in detail.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
SkinHumansScleredema AdultorumScleroderma, LocalizedScleroderma, SystemicDiagnosis, DifferentialScleromyxedema

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research